Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma

Jiashun Zhao

doi:10.47297/wspbtsWSP2755-952104.20250402

PDF
导出
分享
收藏
专辑

Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma

4卷第2期

浏览量: 0 Downloads: 6

Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma
Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma
School of Medical Laboratory and Technology, Harbin Medical University, Harbin, Heilongjiang, 163319, China
2025年4卷第2期页码：21-25
纸质出版：2025-06-30
DOI：10.47297/wspbtsWSP2755-952104.20250402
Accepted：

Scan QR Code

Jiashun Zhao. (2025). Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma. 分析测试学报, 4(2), 21-25.

Zhao Jiashun.Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma[J].Biomedical Testing & Sensing,2025,04(02):21-25.
Jiashun Zhao. (2025). Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma. 分析测试学报, 4(2), 21-25. DOI： 10.47297/wspbtsWSP2755-952104.20250402.

Zhao Jiashun.Molecular Characteristics, Diagnostic and Therapeutic Strategies, and Future Directions of Undifferentiated Pleomorphic Sarcoma[J].Biomedical Testing & Sensing,2025,04(02):21-25. DOI： 10.47297/wspbtsWSP2755-952104.20250402.

摘要

Abstract

Undifferentiated Pleomorphic Sarcoma (UPS)

the most morphologically and genetically heterogeneous soft tissue sarcoma (STS) subtype

poses persistent challenges in clinical diagnosis and treatment. Its aggressive biology and resistance to conventional therapies stem from complex genomic variations

driver mutations

epigenetic dysregulation

and tumor microenvironment (TME) heterogeneity. This review systematically summarizes UPS's molecular genetic features

diagnostic/differential diagnostic approaches

current treatment paradigms

and emerging therapeutic directions—with a focus on immune checkpoint inhibitors

targeted therapy

and multi-omics-guided precision medicine. Integrating existing literature and latest clinical trial data

we provide a theoretical basis for UPS clinical management and prospect future research. Despite ongoing challenges

deepened understanding of tumor heterogeneity and novel therapeutic models are advancing the era of precision diagnosis and treatment for UPS.

关键词

Keywords

references

Jain A., Sharma A., Sarkar R., et al. Comprehensive molecular characterization of undifferentiated pleomorphic sarcoma reveals prognostically significant subtypes[J]. Cancer Cell, 2023, 41(5): 987-1002.

Jones K. B., Barrott J. J., Davidson B. L., et al. The evolving classification of soft tissue sarcoma: from "MFH" to UPS and beyond[J]. Journal of Pathology, 2022, 256(4): 371-384.

Chen X., Zhao G., Wang F., et al. Tumor mutational burden and immune infiltration landscape in undifferentiated pleomorphic sarcoma[J]. Nature Communications, 2021, 12: 6752.

Feng Y., Sun H., Li X., et al. ATRX loss and alternative lengthening of telomeres in UPS drive genomic instability and metastasis[J]. Clinical Cancer Research, 2022, 28(15): 3307-3319.

Gamboa A. C., Dong T., Stawski K., et al. Impact of radiotherapy and surgical margins on survival in patients with undifferentiated pleomorphic sarcoma: a SEER database analysis[J]. Annals of Surgical Oncology, 2023, 30(1): 541-552.

ANTARES Investigators. Nivolumab in patients with rare cancers and high PD-L1 expression (ANTARES): a phase II, open-label, biomarker-directed trial[J]. The Lancet Oncology, 2024, 25(3): e102-e113.

Li B., Li T., Liu J., et al. Remodeling the immune microenvironment via STING activation enhances the efficacy of checkpoint blockade in UPS[J]. Cancer Immunology Research, 2023, 11(7): 880-895.

Perez E. A., Patel S. R., Ludwig J. A., et al. A phase II study of gemcitabine and docetaxel as second-line therapy in advanced undifferentiated pleomorphic sarcoma[J]. The Oncologist, 2022, 27(4): 298-306.

Watson S., Beck L. H., de Reyniès A., et al. Epigenetic profiling identifies distinct UPS subtypes with differential response to EZH2 inhibition[J]. Science Translational Medicine, 2021, 13(621): eabd7781.

UCSF Sarcoma Research Group. Senescent fibroblasts mediate immunosuppression and chemoresistance in the tumor microenvironment of UPS[J]. Cell Metabolism, 2023, 35(6): 1021-1035.

Liu W., Zhang Q., Wang Y., et al. DNA methylation-based classification and prognostic stratification of UPS[J]. Molecular Cancer, 2022, 21: 88.

Toulmonde M., Lucchesi C., Laramas M., et al. PD-1/PD-L1 expression in soft tissue sarcomas: a comparative analysis across histological subtypes[J]. European Journal of Cancer, 2021, 158: 91-102.

Gounder M. M., Razak A. A., Somaiah N., et al. Tazemetostat in advanced epithelioid sarcoma and other sarcomas with INI1 loss: a multicenter phase II study[J]. Journal of Clinical Oncology, 2022, 40(16_suppl): 11500.

Johns Hopkins Immuno-Oncology Team. Induction of tertiary lymphoid structures reprograms the tumor microenvironment and potentiates immunotherapy in cold tumors[J]. Nature, 2024, 628(8007): 184-192.

Fudan University Pancreatic Cancer Program. A multi-omic atlas and prognostic model of pancreatic neuroendocrine tumors[J]. Cancer Cell, 2023, 41(7): 1327-1344.

NOUS-209 Development Team. A shared frameshift peptide neoantigen-based vaccine for cancer interception in Lynch syndrome[J]. Science Immunology, 2023, 8(88): eadj7035.

Sbaraglia M., Righi A., Gambarotti M., et al. The 2020 WHO classification of soft tissue tumours: news and perspectives[J]. Pathologica, 2021, 113(2): 70-84.

Gronchi A., Miah A. B., Dei Tos A. P., et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Annals of Oncology, 2021, 32(11): 1348-1365.

Zheng B., Qu Y., Wang J., et al. Pathologic and molecular heterogeneity in undifferentiated pleomorphic sarcomas[J]. Human Pathology, 2022, 120: 82-94.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma (Version 2.2024)[EB/OL]. [2024-10-20]. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.